Clicky

Achilles Therapeutics plc(ACHL)

Description: Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.


Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Melanoma Antineoplastic Drugs Bladder Cancer Breakthrough Therapy Head And Neck Cancer Orphan Drug Renal Cell Carcinoma Triple Negative Breast Cancer Head And Neck Squamous Cell Carcinoma Advanced Non Small Cell Lung Cancer Immuno Oncology Biopharmaceutical

Home Page: www.achillestx.com

ACHL Technical Analysis

245 Hammersmith Road
London, W6 8PW
United Kingdom
Phone: 44 20 8154 4600


Officers

Name Title
Dr. Iraj Ali CEO & Director
Dr. Karl Peggs M.D. Founder & Chief Medical Officer
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Founder
Dr. Charles Swanton FMEDSCI, M.D., Ph.D. Founder
Dr. Sergio A. Quezada Ph.D. Founder & Chief Scientific Officer
Mr. Robert Coutts Chief Financial Officer
Mr. Lee M. Stern VP of Investor Relations & External Communications
Mr. Daniel Hood Gen. Counsel & Company Sec.
Julia Wilson Head of Communications
Mr. Tariq Ahmed VP of People

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0.1858
Price-to-Book MRQ: 0.2627
Price-to-Sales TTM: 0
IPO Date: 2021-03-31
Fiscal Year End: December
Full Time Employees: 242
Back to stocks